Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:48 AM
Ignite Modification Date:
2025-12-25 @ 4:48 AM
NCT ID:
NCT06189118
Eligibility Criteria:
Inclusion Criteria:
* Ability to provide informed consent (shown as to be able to explain back to the research assistant the purpose of the study as well as voluntary participation, rights, time commitments, etc.)
* MADRS score ≥ 10 (experiencing symptoms of moderate/severe depression) at baseline.
* Participants who have access to internet and basic digital skills to use their computer/tablet. -- Willing and able to attend ≥75% of MBCT or HEP sessions.
* Adequate understanding of English or French.
* Ability to sit for 90 minutes without discomfort.
* Willing to inform if any change is made to their psychotropic medications and dosage for the first 8 weeks of the study
Exclusion Criteria:
* cognitive deficits at baseline, as defined by T-MoCA score \<19.
* diagnosis of post-traumatic stress disorder, bipolar I or II disorder, primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder), and/or severe personality disorder interfering with ability to function in a group setting intervention on a regular basis.
* substance abuse within the past 6 months.
* high suicide risk (e.g., active suicidal ideation and/or recent intent or plan).
* significant visual or hearing impairment
* significant impairments in fine motor skills.
* any medical illnesses that could prevent the participant from engaging in the intervention.
* history of psychiatric hospitalization in the last 3 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
60 Years
Study:
NCT06189118
Study Brief:
Protocol Section:
NCT06189118